Contact
Please use this form to send email to PR contact of this press release:
Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual Meeting
TO: